INmune Bio Phase 2 XPro trial misses primary endpoint; positive subpopulation data at AAIC

Inmune Bio, Inc.

Primary endpoint not met in mITT group; 208 early-AD participants with inflammation biomarkers.
Consistent benefit seen in subpopulation with Aβ pathology and ≥2 inflammatory biomarkers.
Oral presentation at AAIC on July 29, 2025 at 2:00-3:30 PM ET in Toronto.
Company seeking strategic partnership to accelerate XPro development for Alzheimer's.
Publication of full results anticipated by mid-August 2025.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.